ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Endometrial Cancer Recurrent Clinical Trial

Official title:
A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer

Status Active, not recruiting

Clinical Trial Summary

This is a a Simon's two-stage, non-randomized, open label, 2-arm Phase II trial of ONC201 in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03485729
Study type	Interventional
Source	Chimerix
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 21, 2018
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05001282` - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)	Phase 1/Phase 2
Recruiting	`NCT04030429` - Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer	Phase 2
Recruiting	`NCT03621904` - PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Recruiting	`NCT02922764` - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer	Phase 1
Recruiting	`NCT05410717` - CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors	Phase 1
Completed	`NCT03015129` - A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer	Phase 2